Arthritis, Rheumatoid

• 

  Subject Areas on Research

  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 
  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 
  • 4th International Forum on Rheumatoid Arthritis: Great times near the Great Wall. 
  • A comparison of conventional pain coping skills training and pain coping skills training with a maintenance training component: a daily diary analysis of short- and long-term treatment effects. 
  • A comparison of perioperative outcomes in patients with and without rheumatoid arthritis after receiving a total shoulder replacement arthroplasty. 
  • A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis. 
  • A double-blind study comparing benoxaprofen, aspirin, and benoxaprofen plus aspirin in patients with rheumatoid arthritis. 
  • A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. 
  • A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. 
  • A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. 
  • A landmark study on treatment strategies for rheumatoid arthritis. 
  • A molecular basis for MHC class II--associated autoimmunity. 
  • A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls. 
  • A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. 
  • A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. 
  • A randomized controlled trial of home exercise on the rheumatoid hand. 
  • A randomized, controlled trial of emotional disclosure in rheumatoid arthritis: can clinician assistance enhance the effects? 
  • Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis. 
  • Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. 
  • Advances in the treatment of inflammatory arthritis. 
  • Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. 
  • Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis. 
  • Analysis of corneal and conjunctival microenvironments using monoclonal antibodies. 
  • Analyzing pain in rheumatoid arthritis patients. Pain coping strategies in patients who have had knee replacement surgery. 
  • Anterior interosseus nerve injury following elbow arthroscopy. 
  • Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. 
  • Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. 
  • Arthritis syndromes associated with human T cell lymphotropic virus type I infection. 
  • Arthroscopic excision of the radial head: Clinical outcome in 12 patients with post-traumatic arthritis after fracture of the radial head or rheumatoid arthritis. 
  • Arthroscopic resection of the radial head. 
  • Arthrotec: the evidence speaks for itself. 
  • Assessing the consistency of traditional Chinese medicine with multiple correlative active components. 
  • Association of anemia and physical disability among patients with rheumatoid arthritis. 
  • Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. 
  • Autoimmune disease incidence among women prenatally exposed to diethylstilbestrol. 
  • Autoregulation of Tcr V region epitopes in autoimmune disease. 
  • Ayurvedic medicine for rheumatoid arthritis: a systematic review. 
  • B cell tolerance: putting the horse before the cart. 
  • B cell-ablative therapy for the treatment of autoimmune diseases. 
  • B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. 
  • B cells in rheumatoid synovitis. 
  • BLyS and APRIL in rheumatoid arthritis. 
  • Basement membranes and autoimmune diseases. 
  • Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. 
  • Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. 
  • Bone loss, pain and inflammation: three faces of ACPA in RA pathogenesis. 
  • Bone protection by inhibition of microRNA-182. 
  • Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. 
  • CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. 
  • CD19: a promising B cell target for rheumatoid arthritis. 
  • COX-2 inhibitors in rheumatoid arthritis. 
  • CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. 
  • Case reports of heart failure after therapy with a tumor necrosis factor antagonist. 
  • Cationic nanoparticle as an inhibitor of cell-free DNA-induced inflammation. 
  • Cellular targeting in autoimmunity. 
  • Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials. 
  • Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. 
  • Certolizumab pegol. 
  • Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. 
  • Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. 
  • Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. 
  • Chemokines have diverse abilities to form solid phase gradients. 
  • Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. 
  • Chronic Lyme disease: the controversies and the science. 
  • Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. 
  • Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. 
  • Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. 
  • Clinician's comment on the management of pain in arthritis. 
  • Cognitive behavioral control of arthritis pain. 
  • Cognitive-behavioral treatment of rheumatoid arthritis pain: maintaining treatment gains. 
  • Collagen, collagenase and clinicians. 
  • Collagenase: its physiological and pathological role. 
  • Collagenolytic activity of synovium in rheumatoid arthritis. 
  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. 
  • Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis. 
  • Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. 
  • Comparison of perioperative complications in patients with and without rheumatoid arthritis who receive total elbow replacement. 
  • Comparison of symptoms, treatment, and outcomes of coronary artery disease among rheumatoid arthritis and matched subjects undergoing percutaneous coronary intervention. 
  • Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy. 
  • Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. 
  • Coping with rheumatoid arthritis pain: catastrophizing as a maladaptive strategy. 
  • Correlates of fatigue in older adults with rheumatoid arthritis. 
  • Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders. 
  • Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. 
  • Custom intramedullary intercalating device for treatment of supracondylar fracture between constrained total knee arthroplasty and well-fixed total hip arthroplasty. 
  • Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synovium. 
  • Dehydroascorbate transport in human chondrocytes is regulated by hypoxia and is a physiologically relevant source of ascorbic acid in the joint. 
  • Depression and level of functioning in patients with rheumatoid arthritis. 
  • Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. 
  • Development of an observation method for assessing pain behavior in rheumatoid arthritis patients. 
  • Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. 
  • Differential regulation of leucocyte L-selectin (CD62L) expression in normal lymphoid and inflamed extralymphoid tissues. 
  • Digitalgia paresthetica with digital neuropathy in rheumatoid arthritis. 
  • Disease severity and domain-specific arthritis self-efficacy: relationships to pain and functioning in patients with rheumatoid arthritis. 
  • Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. 
  • Disseminated infection with rapidly growing mycobacteria. 
  • Does a lack of physical activity explain the rheumatoid arthritis lipid profile? 
  • Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. 
  • Early detection of carpal erosions in patients with rheumatoid arthritis: a pilot study of magnetic resonance imaging. 
  • Early rheumatoid arthritis. 
  • Editorial: Insulin Resistance: Releasing the Brakes on Synovial Inflammation and Osteoarthritis? 
  • Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. 
  • Effect of anti-CD4 antibody treatment on inflammatory arthritis in MRL-lpr/lpr mice. 
  • Effect of motorized scooters on physical performance and mobility: a randomized clinical trial. 
  • Effectiveness of rheumatoid hand surgery: contrasting perceptions of hand surgeons and rheumatologists. 
  • Effectiveness of self-instruction for arthritis patient education. 
  • Effects of D-penicillamine on neuromuscular transmission in rats. 
  • Effects of day-to-day affect regulation on the pain experience of patients with rheumatoid arthritis. 
  • Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. 
  • Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. 
  • Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. 
  • Engraftment of human synovium into severe combined immune deficient mice. Migration of human peripheral blood T cells to engrafted human synovium and to mouse lymph nodes. 
  • Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. 
  • Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. 
  • Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel. 
  • Everyday life with osteoarthritis or rheumatoid arthritis: independent effects of disease and gender on daily pain, mood, and coping. 
  • Expression of E-selectin messenger RNA and protein in rheumatoid arthritis. 
  • Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. 
  • Fertility and infertility in rheumatoid arthritis. 
  • Fine-needle aspiration cytology of articular and periarticular lesions. 
  • Foot and ankle problems in rheumatoid arthritis. 
  • Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials. 
  • Fusion with occipital bone for atlantoaxial instability: technical note. 
  • Gastrointestinal microbleeding: comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents. 
  • Genetic analysis of multiplex rheumatoid arthritis families. 
  • Genetic control of inflammatory arthritis and glomerulonephritis in congenic lpr mice and their F1 hybrids. 
  • Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases. 
  • Glycoprotein 96 perpetuates the persistent inflammation of rheumatoid arthritis. 
  • Good and bad memories following rituximab therapy. 
  • Hallux Varus: An Underreported Presentation of Rheumatoid Arthritis. 
  • Haplotype-based analysis: a summary of GAW16 Group 4 analysis. 
  • Health-related quality of life among older adults with arthritis. 
  • Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. 
  • Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. 
  • Hepatoxicity with encephalopathy associated with aspirin therapy in rheumatoid arthritis. 
  • Heterotopic ossification complicating total elbow replacement in a patient with rheumatoid arthritis. 
  • Hindfoot Arthritis Progression and Arthrodesis Risk After Total Ankle Replacement. 
  • How the gut inflames the joints. 
  • Hydroxychloroquine-induced hyperpigmentation: the staining pattern. 
  • Hypothetical bias, cheap talk, and stated willingness to pay for health care. 
  • IL-17 Production of Neutrophils Enhances Antibacteria Ability but Promotes Arthritis Development During Mycobacterium tuberculosis Infection. 
  • IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. 
  • Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. 
  • Immigration check for neutrophils in RA lining: laminin alpha5 low expression regions act as exit points. 
  • Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. 
  • Impact of Diabetes on Outcome of Total Ankle Replacement. 
  • Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. 
  • Increase in TCR gamma delta T lymphocytes in synovia from rheumatoid arthritis patients with active synovitis. 
  • Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients. 
  • Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. 
  • Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. 
  • Inflammatory cytokines and cellular metabolites as synovial fluid biomarkers of posttraumatic ankle arthritis. 
  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. 
  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. 
  • Infliximab for the treatment of early rheumatoid arthritis. 
  • Infliximab in active early rheumatoid arthritis. 
  • Infliximab treatment for rheumatic disease: clinical and radiological efficacy. 
  • Infliximab treatment maintains employability in patients with early rheumatoid arthritis. 
  • Influence of hypoxia and reoxygenation on cytokine-induced production of proinflammatory mediators in articular cartilage. 
  • Informed consent in a clinical trial of a novel treatment for rheumatoid arthritis. 
  • Interleukin 10 treatment for rheumatoid arthritis. 
  • Interleukin-10: therapeutic prospects in rheumatoid arthritis. 
  • Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo. 
  • Interleukin-2 receptor levels in the sera of rheumatoid arthritis patients treated with methotrexate. 
  • Leukocyte homing to synovium. 
  • Lipid testing in patients with rheumatoid arthritis and key cardiovascular-related comorbidities: a medicare analysis. 
  • Localization of collagenase mRNA in rheumatoid arthritis synovium by in situ hybridization histochemistry. 
  • Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. 
  • Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. 
  • Managing contraception and pregnancy in the rheumatologic diseases. 
  • Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. 
  • Mechanical sensation and pain thresholds in patients with chronic arthropathies. 
  • Mechanism of hypochlorite-mediated inactivation of proteinase inhibition by alpha 2-macroglobulin. 
  • Mechanisms of inflammation and leukocyte chemotaxis in the rheumatic diseases. 
  • Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy. 
  • Memory for pain: the relationship of pain catastrophizing to the recall of daily rheumatoid arthritis pain. 
  • Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. 
  • Metacarpophalangeal and interphalangeal joint reconstruction: use of silicone rubber-dacron prostheses for replacement of irreparable joints of the hand. 
  • Metatarsal head resection for rheumatoid deformities of the forefoot. 
  • Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. 
  • Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. 
  • Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients. 
  • Molecular alterations in skeletal muscle in rheumatoid arthritis are related to disease activity, physical inactivity, and disability. 
  • Multilammelated structures in muscle external lamina. 
  • Musculoskeletal syndromes associated with malignancy. 
  • NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. 
  • Neck pain in the elderly: a management review. Part I. 
  • Neck pain in the elderly: a management review. Part II. 
  • New therapeutics in rheumatoid arthritis. 
  • New treatments for rheumatoid arthritis. 
  • Niclosamide: Beyond an antihelminthic drug. 
  • Niebauer trapeziometacarpal arthroplasty: a long-term follow-up. 
  • Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. 
  • Nitric oxide synthase and cyclooxygenase interactions in cartilage and meniscus: relationships to joint physiology, arthritis, and tissue repair. 
  • Nonmelanoma skin cancer in inflammatory bowel disease: a review. 
  • Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. 
  • Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis. 
  • Osteoarthritis--a case for personalized health care? 
  • Osteonecrosis of the lateral aspect of the talar dome after triple arthrodesis. A report of three cases. 
  • Osteoporosis. 
  • Oxidized alpha2-macroglobulin (alpha2M) differentially regulates receptor binding by cytokines/growth factors: implications for tissue injury and repair mechanisms in inflammation. 
  • Oxygen, nitric oxide and articular cartilage. 
  • Pain and functioning of rheumatoid arthritis patients based on marital status: is a distressed marriage preferable to no marriage? 
  • Pain behavior in rheumatoid arthritis patients: identification of pain behavior subgroups. 
  • Pain coping strategies and coping efficacy in rheumatoid arthritis: a daily process analysis. 
  • Pain in the rheumatic diseases. Practical aspects of diagnosis and treatment. 
  • Pain, physical functioning, and overeating in obese rheumatoid arthritis patients: do thoughts about pain and eating matter? 
  • Patient predictors of caregiver burden, optimism, and pessimism in rheumatoid arthritis. 
  • Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. 
  • Patient-physician discussions about costs: definitions and impact on cost conversation incidence estimates. 
  • Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. 
  • Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. 
  • Pectoralis pyomyositis: an unusual cause of chest wall pain in a patient with diabetes mellitus and rheumatoid arthritis. 
  • Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. 
  • Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. 
  • Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. 
  • Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis. 
  • Plasminogen activation stimulates an increase in intracellular calcium in human synovial fibroblasts. 
  • Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. 
  • Posterior tibial tendon dysfunction in rheumatoid arthritis. 
  • Potential pathogenicity of deglycosylated IgG cross reactive with streptokinase and fibronectin in the serum of patients with rheumatoid arthritis. 
  • Prediction of pain behavior and functional status of rheumatoid arthritis patients using medical status and psychological variables. 
  • Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. 
  • Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis. 
  • Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. 
  • Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. 
  • Pregnancy and rheumatoid arthritis: insights into the immunology of fetal tolerance and control of autoimmunity. 
  • Pregnancy in rheumatoid arthritis: a retrospective study. 
  • Progress in the treatment of rheumatoid arthritis. 
  • Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. 
  • Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. 
  • Prosthetic arthroplasty of the hand. 
  • Psychological approaches to understanding and treating arthritis pain. 
  • Psychological well-being among people with recently diagnosed rheumatoid arthritis. Do self-perceptions of abilities make a difference? 
  • Psychosocial assessment of pain in patients having rheumatic diseases. 
  • Pulmonary hypertension secondary to serum hyperviscosity in a patient with rheumatoid arthritis. 
  • Pyoderma gangrenosum: a reappraisal of associated systemic diseases. 
  • Radiation synovectomy with 165Dy-FHMA: lymph node uptake and radiation dosimetry calculations. 
  • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. 
  • Radiographic joint damage in rheumatoid arthritis: a community-based perspective. 
  • Ratio of Range of Motion of the Ankle and Surrounding Joints After Total Ankle Replacement: A Radiographic Cohort Study. 
  • Reactive effects of diary self-assessment in chronic pain patients. 
  • Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. 
  • Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus. 
  • Recent advances and future directions in the biopsychosocial assessment and treatment of arthritis. 
  • Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). 
  • Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. 
  • Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. 
  • Reticuloendothelial system fc receptor function in rheumatoid arthritis. 
  • Retinal nerve fibre layer thickness measurements in patients using chloroquine. 
  • Retinal vascular calibre is altered in patients with rheumatoid arthritis: a biomarker of disease activity and cardiovascular risk? 
  • Retinal venular calibre is increased in patients with autoimmune rheumatic disease: a case-control study. 
  • Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. 
  • Rhenium heptasulfide: a potential carrier system for radiation synovectomy. 
  • Rheumatoid arthritis and sterile corneal ulceration. Analysis of tissue immune effector cells and ocular epithelial antigens using monoclonal antibodies. 
  • Rheumatoid arthritis complicates noninvasive whole blood gene expression testing for coronary artery disease. 
  • Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. 
  • Rheumatology in the current era: the challenge of success. 
  • Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. 
  • Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. 
  • Robust test method for time-course microarray experiments. 
  • Role of adhesion molecules in the pathogenesis of rheumatoid arthritis. 
  • Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. 
  • Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. 
  • Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis. 
  • Self-Efficacy and Adherence Behaviors in Rheumatoid Arthritis Patients. 
  • Self-efficacy for exercise, more than disease-related factors, is associated with objectively assessed exercise time and sedentary behaviour in rheumatoid arthritis. 
  • Serial measurement of serum interleukin-2 receptor levels in patients with rheumatoid arthritis: limited evidence for a role of T cell activation in clinical exacerbations. 
  • Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. 
  • Serum levels of soluble CD44 in primary Sjögren's syndrome. 
  • Serum, urinary, and salivary nitric oxide in rheumatoid arthritis: complexities of interpreting nitric oxide measures. 
  • Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis. 
  • Single Cell Chemical Cytometry of Akt Activity in Rheumatoid Arthritis and Normal Fibroblast-like Synoviocytes in Response to Tumor Necrosis Factor α. 
  • Sjögren's syndrome (Sicca syndrome): current issues. 
  • Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177). 
  • Soluble recombinant neutral endopeptidase (CD10) as a potential antiinflammatory agent. 
  • Stability analysis for drugs with multiple active ingredients. 
  • Sterile corneal melting and necrotizing scleritis after cataract surgery in patients with rheumatoid arthritis and collagen vascular disease. 
  • Streptokinase and human fibronectin share a common epitope: implications for regulation of fibrinolysis and rheumatoid arthritis. 
  • Stress and rheumatoid arthritis: can a cognitive coping model help explain a link? 
  • Summary of contributions to GAW15 Group 13: candidate gene association studies. 
  • Suppression of inflammatory disease activity in rheumatoid arthritis is associated with improvements in retinal microvascular health. 
  • Surgical management of the rheumatoid hand: consensus and controversy among rheumatologists and hand surgeons. 
  • Susceptibility to childhood-onset rheumatoid arthritis: investigation of a weighted genetic risk score that integrates cumulative effects of variants at five genetic loci. 
  • Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. 
  • Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. 
  • Synovectomy of the rheumatoid knee using intra-articular injection of dysprosium-165-ferric hydroxide macroaggregates. 
  • Synovial microenvironment-T cell interactions. Human T cells bind to fibroblast-like synovial cells in vitro. 
  • Synovial mononuclear phagocytes in rheumatoid arthritis and osteoarthritis: quantitative and functional aspects. 
  • T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. 
  • TLR3 Ligand Poly(I:C) Exerts Distinct Actions in Synovial Fibroblasts When Delivered by Extracellular Vesicles. 
  • Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. 
  • Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study. 
  • Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers. 
  • Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. 
  • The 1978 annual meeting of the American Rheumatism Association. 
  • The BRIC-GARN Meeting 2011: of mice and men. 
  • The Duke University Arthritis Center. 
  • The assessment of pain in rheumatoid arthritis. Validity of a behavioral observation method. 
  • The assessment of pain in rheumatoid arthritis: disease differentiation and temporal stability of a behavioral observation method. 
  • The clinical experience with silicone-dacron metacarpophalangeal and interphalangeal joint prostheses. 
  • The current state of care in gout: Addressing the need for better understanding of an ancient disease. 
  • The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). 
  • The effect of dynamic mechanical compression on nitric oxide production in the meniscus. 
  • The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. 
  • The effects of nonsteroidal antiinflammatory drug therapy in early rheumatoid arthritis on serum levels of soluble interleukin 2 receptor, CD4, and CD8. 
  • The effects of written emotional disclosure and coping skills training in rheumatoid arthritis: a randomized clinical trial. 
  • The eye: a window of opportunity in rheumatoid arthritis? 
  • The failed total ankle. 
  • The future of rheumatoid arthritis treatment. 
  • The impact of menopause on functional status in women with rheumatoid arthritis. 
  • The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. 
  • The morphology of the femur in developmental dysplasia of the hip. 
  • The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. 
  • The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. 
  • The relationship of arthritis self-efficacy to daily pain, daily mood, and daily pain coping in rheumatoid arthritis patients. 
  • The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. 
  • The role of leukocyte adhesion molecules in cellular interactions: implications for the pathogenesis of inflammatory synovitis. 
  • The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. 
  • The specialized centers of research in rheumatoid arthritis. Recent progress and prospects for future advances. 
  • The value of serial postoperative radiographs of total knee arthroplasties. 
  • Therapeutic approaches to the treatment of rheumatoid disease. 
  • Therapy of rheumatoid arthritis: new developments and trends. 
  • Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. 
  • Tides of inflammation: impact of biologics. 
  • Toll-like receptor signaling: common pathways that drive cardiovascular disease and rheumatoid arthritis. 
  • Total lymphoid irradiation as an immunosuppressive agent for transplantation and the treatment of 'autoimmune' disease: a review. 
  • Treatment of Mycobacterium haemophilum infection with an antibiotic regimen including clarithromycin. 
  • Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. 
  • Treatment of early rheumatoid arthritis. 
  • Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression. 
  • Treatment of rheumatoid arthritis with a DR4/1 peptide. 
  • Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. 
  • Treatment of rheumatoid synovitis of the knee with intraarticular injection of dysprosium 165-ferric hydroxide macroaggregates. 
  • Tuberculosis in the cytokine era: what rheumatologists need to know. 
  • Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. 
  • Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. 
  • Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. 
  • Ulnar nerve function following total elbow arthroplasty: a prospective study comparing preoperative and postoperative clinical and electrophysiologic evaluation in patients with rheumatoid arthritis. 
  • Understanding the adoption of arthritis self-management: stages of change profiles among arthritis patients. 
  • Up-regulation of the alpha2-macroglobulin signaling receptor on rheumatoid synovial fibroblasts. 
  • Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. 
  • Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. 
  • What rheumatologists in the United States think of complementary and alternative medicine: results of a national survey. 
  • [Prayers for patients with internal and cardiological diseases--an applicable therapeutic method?]. 
  • alpha(2)-Macroglobulin from rheumatoid arthritis synovial fluid: functional analysis defines a role for oxidation in inflammation. 
• 

  Keywords of People

  • Allen, Kelli Dominick, Adjunct Professor in the Department of Medicine, Medicine, General Internal Medicine
  • Allen, Nancy Bates, Professor of Medicine, Medicine, Rheumatology and Immunology
  • Kelsoe, Garnett H., James B. Duke Professor of Immunology, Immunology
  • Krangel, Michael S., Mary Bernheim Professor of Immunology, Immunology
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society